Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 3/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010459 | 0.84 | DYRK1A (0.44) | KDM4EHTTNCOA3CLK1DYRK1A | |
| SCHEMBL31401046 | 0.74 | IMPDH2 (0.50) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7751472 | 0.74 | CYP2A6 (0.57) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18544875 | 0.74 | HTT (0.44) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL245899 | 0.74 | IMPDH2 (0.50) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3386889 | 0.74 | IMPDH2 (0.50) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL246633 | 0.74 | F12 (0.57) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL277425 | 0.74 | KDM4E (0.53) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30692011 | 0.74 | F12 (0.57) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL277424 | 0.74 | CYP3A4 (0.44) | KDM4ELMNACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383750-B1 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-26 | — | — | EP | claimed |
| EP-1622867-B1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-19 | — | — | EP | claimed |
| US-7253171-B2 | Urea derivatives as integrin α4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-07 | — | — | US | claimed |
| US-20070179183-A1 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ALMIRALL, S.A. (ES) | 2007-08-02 | — | — | US | claimed |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2004-07-22 | — | — | US | claimed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2133343-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20070179183-A1 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ALMIRALL, S.A. (ES) | 2007-08-02 | — | — | US | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1622867-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| WO-2004099126-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN α4 ANTAGONISTS | ALMIRALL PRODESFARMA SA (ES) | 2004-11-18 | — | — | WO | disclosed |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2004-07-22 | — | — | US | disclosed |
| EP-1383750-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002057242-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | KDM4E 3259/4885LMNA 2860/4885CYP1A2 365/4885 |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | OSTC, EEF1D, SQLE | KDM4E 2563/4885LMNA 1929/4885CYP1A2 1135/4885 |
| US-20070179183-A1 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ITGA4, ITGB4, ITGA2 | KDM4E 594/4885LMNA 4237/4885CYP1A2 3204/4885 |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | ITGA4, ITGB4, ITGA1 | KDM4E 1230/4885LMNA 2794/4885CYP1A2 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.